Skip to main content

Pharma News

 

Clinical courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Gilead Sciences, Inc. announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tenofovir alafenamide (TAF) 25 mg, an investigational, once-daily treatment for adults with chronic hepatitis B virus (HBV) infection.

  • Volpara Solutions, the leading provider of automated breast density assessment and quantitative breast imaging tools, announced  that it has received a new 510(k) clearance from the U.S. Food & Drug Administration (FDA) for Volpara Density Maps, a new solution designed to help radiologists address the requirement in the BI-RADS 5th Edition Atlas to provide “an overall assessment of the volume of attenuating tissues in the breast, to help indicate the relative possibility that a lesion could be obscured.”

    (adsbygoogle = window.adsbygoogle || []).push({});
  • Pluristem Therapeutics Inc, a leading developer of placenta-based cell therapy products, announced that the U.S. Food and Drug Administration (FDA) cleared the Company’s Investigational New Drug (IND) application to begin its Phase I trial of PLX-R18 cells to treat incomplete hematopoietic recovery following Hematopoietic Cell Transplantation (HCT). The clinical trial is expected to begin in the first half of 2016.

  • The National Institute of Cholera and Enteric Diseases (NICED), a premier institute under the Indian Council of Medical Research (ICMR), is in talks with the West Bengal government to introduce a cholera vaccine ahead of the peak season as a preventive measure.

  • The National Institute of Cholera and Enteric Diseases (NICED) here on Friday inked a deal with the Bengal Chamber of Commerce and Industry (BCCI) to undertake cutting-edge research on enteric diseases including hepatitis C, and see through translation of research outputs for community outreach.

Subscribe to Pharma News